ERBB2 and breast cancer: In contrast to the rapid tumor progression observed in several transgenic strains carrying the activated neu transgene, wild-type neu expression in the mammary epithelium results in the development of focal mammary tumors with longer latency than those with constitutively active neu (8–12 months vs. 6–7 months) [16], [17].